癌症药物基因组学。
Cancer pharmacogenomics.
机构信息
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2011 Sep;90(3):461-6. doi: 10.1038/clpt.2011.126. Epub 2011 Jul 27.
Abstract
Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.
摘要
药物基因组学研究正在产生分子诊断工具，可用于优化个体患者的药物选择和剂量。鉴于大多数抗癌药物的治疗指数较窄，以及治疗不足的严重后果，癌症化疗是将药物基因组学转化为临床应用的一个极有吸引力的治疗领域。本文讨论了遗传（种系）和获得性（体细胞）基因组变异源如何改变癌症化疗的毒性或疗效。
相似文献
1
Cancer pharmacogenomics.
Clin Pharmacol Ther. 2011 Sep;90(3):461-6. doi: 10.1038/clpt.2011.126. Epub 2011 Jul 27.
2
Response to "personalized medicine, genomics, and pharmacogenomics".
Clin J Oncol Nurs. 2014 Dec;18(6):618. doi: 10.1188/14.CJON.618.
3
Precision in cancer pharmacogenomics.
Pharmacogenomics. 2020 Apr;21(5):311-316. doi: 10.2217/pgs-2020-0011. Epub 2020 Apr 3.
4
Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities.
Cancer Cell. 2021 Jun 14;39(6):730-733. doi: 10.1016/j.ccell.2021.04.013. Epub 2021 May 20.
5
Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Drug Metab Pers Ther. 2016 Mar;31(1):25-34. doi: 10.1515/dmpt-2015-0042.
6
Application of pharmacogenomics in supportive oncology: a patient journey.
Pharmacogenomics. 2022 Oct;23(15):807-811. doi: 10.2217/pgs-2022-0133. Epub 2022 Oct 14.
7
A Platform for Comprehensive Genomic Profiling in Human Cancers and Pharmacogenomics Therapy Selection.
Methods Mol Biol. 2018;1825:413-424. doi: 10.1007/978-1-4939-8639-2_14.
8
Clinical implementation of pharmacogenetics.
Drug Metab Pers Ther. 2016 Mar;31(1):9-16. doi: 10.1515/dmpt-2015-0031.
9
New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics.
Drug Metab Pers Ther. 2018 Jun 27;33(2):61-64. doi: 10.1515/dmpt-2018-0008.
10
Health: Make precision medicine work for cancer care.
Nature. 2015 Apr 16;520(7547):290-1. doi: 10.1038/520290a.
引用本文的文献
1
Genomic signatures of selection in drug metabolizing genes across cattle populations.
Mamm Genome. 2025 Jun 17. doi: 10.1007/s00335-025-10139-7.
2
Germline variants in cancer therapy.
Cancer Drug Resist. 2019 Mar 19;2(1):18-30. doi: 10.20517/cdr.2019.05. eCollection 2019.
3
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.
Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966.
4
Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.
Eur J Clin Pharmacol. 2016 May;72(5):545-53. doi: 10.1007/s00228-016-2015-3. Epub 2016 Jan 23.
5
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
J Natl Cancer Inst. 2015 Jul 9;107(10). doi: 10.1093/jnci/djv188. Print 2015 Oct.
6
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.
Blood Rev. 2015 Jul;29(4):243-9. doi: 10.1016/j.blre.2015.01.001. Epub 2015 Jan 10.
7
Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.
Pharmacogenomics. 2014 Nov;15(14):1771-1790. doi: 10.2217/pgs.14.117.
8
Pharmacogenomics in oncology care.
Front Genet. 2014 Apr 8;5:73. doi: 10.3389/fgene.2014.00073. eCollection 2014.
9
Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation.
Eur J Hum Genet. 2014 Jun;22(6):715-23. doi: 10.1038/ejhg.2013.247. Epub 2013 Nov 20.
10
Pharmacogenomics in early-phase clinical development.
Pharmacogenomics. 2013 Jul;14(9):1085-97. doi: 10.2217/pgs.13.81.
本文引用的文献
1
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.
Nat Med. 2011 Sep 25;17(10):1298-303. doi: 10.1038/nm.2430.
2
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Clin Pharmacol Ther. 2011 May;89(5):708-17. doi: 10.1038/clpt.2011.27. Epub 2011 Mar 30.
3
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.
4
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.
5
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
Nat Genet. 2011 Mar;43(3):237-41. doi: 10.1038/ng.763. Epub 2011 Feb 6.
6
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26.
7
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.
Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.
8
Pharmacogenomics in pediatric leukemia.
Curr Opin Pediatr. 2010 Dec;22(6):703-10. doi: 10.1097/MOP.0b013e32833fde85.
9
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.
Clin Cancer Res. 2010 Sep 1;16(17):4468-77. doi: 10.1158/1078-0432.CCR-10-0478. Epub 2010 Jun 1.
10
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Expert Opin Drug Saf. 2010 Jan;9(1):23-37. doi: 10.1517/14740330903426151.
Zotero 插件